Taken together, our model simulations suggest the value of targeting IL-4 axis in tumor, especially the therapeutic blockade of IL-4/receptor interaction (e.g. inhibiting IL-4Rα, a receptor subunit utilized in both IL-4 and IL-13 signaling) as a potential approach to modulate macrophage-mediated immune response to combat tumor progression. This evidence concerns the gene IL4R and neoplasm.